Literature DB >> 3295578

Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors.

R G Hill, J Hughes, K M Pittaway.   

Abstract

Cholecystokinin octapeptide (CCK 8) produced significant antinociception in the tail immersion test in the rat, paw pressure test in the rat and acetylcholine-induced writhing test in the mouse after subcutaneous (s.c.) administration. In the hot plate test, CCK 8 (s.c.) showed antinociceptive activity if the latency to lick was used as the end point but if the latency to jump was recorded the antinociceptive effects were not evident. Cholecystokinin tetrapeptide (CCK 4) was shown to be antinociceptive in the writhing but not in the hot plate test after subcutaneous administration and appeared to be less potent than CCK 8 when tested under the same conditions. Antinociception induced by CCK 8 in the hot plate test (lick) could also be demonstrated after direct intracerebroventricular (i.c.v.) injection and this observation was also made with the CCK-related peptide FMRF amide. Antinociception induced by CCK 8 (which did not appear to be associated with reduced locomotor activity) was evident 5 min after intraventricular injection and was maximal at 10 min, the effect lasting over a 30-45 min period. The antinociceptive effect of CCK 8 was antagonised by naloxone and was potentiated by simultaneous administration of the peptidase inhibitors bestatin, thiorphan and captopril.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3295578     DOI: 10.1016/0028-3908(87)90180-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.

Authors:  Z Wiesenfeld-Hallin; X J Xu; J Hughes; D C Horwell; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 2.  Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction.

Authors:  B P Roques; F Noble
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

3.  Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.

Authors:  L Singh; R J Oles; M J Field; P Atwal; G N Woodruff; J C Hunter
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

4.  Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain.

Authors:  F Noble; M Derrien; B P Roques
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

5.  Influences of cholecystokinin octapeptide on phosphoinositide turnover in neonatal-rat brain cells.

Authors:  L J Zhang; X Y Lu; J S Han
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

6.  Reduction of food intake by central administration of cholecystokinin octapeptide in the rat is dependent upon inhibition of brain peptidases.

Authors:  T Griesbacher; G E Leighton; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.